MOLECULAR EVALUATION OF CELL CYCLE INHIBITORS AFTER Hepatocellular carcinoma (HCC) TREATMENT In Vitro

Authors

  • M. Y. NASR Molecular Cell Biology & Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, (GEBRI)University of Sadat City
  • MONA M. DARWISH Chemistry Department, Faculty of Sciences, Zagazig University
  • A. F. ELSABRUTI Postgraduate Researcher, Alexandria University
  • WA. H. ROSHDY Central Public Health Laboratories, Ministry of Health and Population, Cairo
  • H. A. EL-RABEAY Bioinformatics Department Genetic Engineering and Biotechnology Research Institute, (GEBRI) University of Sadat City

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent types of cancer. HCC is the sixth most popular cancer in the world and the fourth most common cancer in Egypt, respectively. Egypt is the third and fifteenth most populated countries in Africa and the globe, respectively. The goal of this study is to examine the effect of graphene quantum dots (GQDs) on the expression of P21 & c-MYC genes on a cell line in liver cancer namely "HuH-7 cell line." The area of studying the anticancer effect of GQDs is attracting growing attention because of its valuable properties. Especially due to its nano- sized sheets, it tends to infiltrate the cell nucleus and interfere with DNA function due to its ultra-small size. The results emphasize the validity of using GQDs as anticancer agent, with varied concentrations of GQDs inhibiting the development of cancer cells (HuH-7) via gene up regulation.

References

Balogh J., Victor D., Asham E. H., Bur- roughs S. G., Boktour M., Saharia A., Li X., Ghobrial R. M. and Monsour H. P., (2016). Hepatocellular carcinoma: A Review. Journal of hepatocellular carcinoma. 5:41-53. Retrieved September 23,

, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063561

Bosch F. X., Ribes J., Díaz M. and Cléries R., (2004). Primary liver cancer: Worldwide incidence and Trends. Gastroenterology, 127(5):s5-s16 https://doi.org/10.1053/j.gastro.2004.09.011

Brenner C., Deplus R., Didelot C., Loriot A., Vir E., De Smet C., Gutierrez A., Danovi D., Bernard D., Boon T., Giuseppe Pelicci P., Amati B., Kouzarides T., de Launoit Y., Di Croce L. and Fuks F., (2004). Myc represses transcription through recruitment of DNA methyltransferase corepressor. The EMBO Journal, 24(2): 336-346. https://doi.org/10.1038/sj.emboj.7600509

Cancer facts and figures (2022). American Cancer Society. (n.d.). from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022. html#:~:text=The Facts & Figures annual report,deaths in the United States.

Colditz G. A., Sellers T. A. and Trapido E., (2005). Epidemiology-identifying the causes and preventability of cancer? Nature Reviews Cancer, 6:75-83. https://doi.org/10.1038/nrc1784

Faguet G. B. (2015). A brief history of cancer: age-old milestones underlying our current knowledge database. International journal of cancer, 136: 2022-2036.

Harper J. W., Adami G. R., Wei N., Keyomarsi K. and Elledge S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816.

Iannazzo D., Celesti C. and Espro C., (2020). Recent advances on graphene quantum dots as multifunctional Nanoplatforms for cancer treatment. Biotechnology Journal, 16(2):1-13. 1900422. https://doi.org/10.1002/biot.201900422

Ioannou G. N., Splan M. F., Weiss N. S., McDonald G. B., Beretta L. and Lee S. P., (2007). Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clinical Gastroenterology and Hepatology, 5(8):938-945. https://doi.org/10.1016/j.cgh.2007.02.039

Lin C. P., Liu C. R., Lee C. N., Chan T. S. and Liu H. E., (2010). Targeting C-myc as a novel approach for hepatocellular carcinoma. World Journal of Hepatology, 2(1): 16-20. https://doi.org/10.4254/wjh.v2.i1.16

Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol Methods. Dec 16, 65 (1-2):55-63. doi:10.1016/0022-1759(83)90303-4. PMID: 6606682.

Mousses S., Ozçelik H., Lee P. D., Mal- kin D., Bull S. B. and Andrulis I. L., (1995). Two variants of the CIP1/WAF1gene occur together and are associated with human cancer. Hum. Mol. Genet., 4: 1089-1092.

O'Connor S., Ward J. W., Watson M., Momin B. and Richardson L. C., (2010). Hepatocellular carcinoma- United States, 2001-2006. Morbidity and Mortality Weekly Report, 59(17): 517-520.

Prochownik E. V. (2004). C-myc as a therapeutic target in cancer. Expert Review of Anticancer Therapy, 4(2): 289-302. https://doi.org/10.1586/14737140.4.2.289

Shachaf C. M., Kopelman A. M., Arvanitis C., Karlsson Å., Beer S., Mandl S., Bachmann M. H., Borowsky A. D., Ruebner B., Cardiff R. D., Yang Q., Bishop J. M., Contag C. H. and Felsher D. W., (2004). Myc inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature, 431(7012): 1112-1117. https://doi.org/10.1038/nature03043

Sanna V., Pala N. and Sechi M., (2014). January 15). Targeted therapy using nanotechnology: Focus on cancer: IJN. International Journal of Nanomedicine. 9:467-483. Retrieved from https://doi.org/10.2147%2FIJN.S36654

Shamloo and Usluer. (2019). P21 in cancer research. Cancers, 11(8): 1178. https://doi.org/10.3390/cancers11081178

Shi J., Kantoff P. W., Wooster R. and Farokhzad O. C., (2016). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1): 20-37. https://doi.org/10.1038/nrc.2016.108

Wan M., Cofer K. and Dubeau L., (1996). WAF1/CIP1 structural abnormalities do not contribute to cell cyclederegulation in ovarian cancer. Br. J. Cancer, 73: 1398-1400. doi:10.1038/bjc.1996.265.

Xia Haoran, Ma Zhu, Xiao Zheng, Zhou Weiya, Zhang Hua, Du Caichen, Zhuang Jia, Cheng Xiaowei, Xingchong Liu and Yuelong Huang, (2019). Interfacial modification using ultrasonic atomized graphene quantum dots for efficient perovskite solar cells, Organic Electronics, Vol. 75, 105-415, ISSN 1566-1199, https://doi.org/10.1016/j.orgel.2019.105415

Xu C., Yan Z., Zhou L. and Wang Y., (2013). A comparison of glypican- 3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: A meta-analysis. Journal of Cancer Research and Clinical Oncology, 139(8): 1417-1424. https://doi.org/10.1007/s00432-013-1458-5

Younis M. R., He G., Lin J. and Huang P., (2020). Recent advances on graphene quantum dots for bioimaging applications. Frontiers in Chemistry, 8:424. https://doi.org/10.3389/fchem.2020.00424

Zugazagoitia J., Guedes C., Ponce S., Ferrer I., Molina-Pinelo S. and Paz-Ares L., (2016). Current challenges in cancer treatment. Clinical Therapeutics, 38(7): 1551-1566. https://doi.org/10.1016/j.clinthera.2016.03.026

Downloads

Published

2022-12-11

Issue

Vol. 51 No. 1 (2022)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.